The Iressa Survival Evaluation in Lung Cancer (ISEL) phase III study was similar to the NCIC BR.21 trial design as it compared an EGFR TKI to placebo in EGFR mutation-unselected NSCLC patients in the second and third line setting (7). This evidence concerns the gene EGFR and non-small cell lung carcinoma.